Stockman Wealth Administration Inc. decreased its stake in shares of Bristol-Myers Squibb Firm (NYSE:BMY) by eight.7% within the 2nd quarter, in line with the corporate in its most up-to-date Kind 13F submitting with the SEC. The agency owned 21,305 shares of the biopharmaceutical firm’s inventory after promoting 2,030 shares in the course of the quarter. Bristol-Myers Squibb makes up roughly 1.2% of Stockman Wealth Administration Inc.’s portfolio, making the inventory its 29th largest place. Stockman Wealth Administration Inc.’s holdings in Bristol-Myers Squibb had been value $1,187,00zero as of its most up-to-date SEC submitting.
Different hedge funds additionally not too long ago purchased and bought shares of the corporate. Meiji Yasuda Life Insurance coverage Co raised its place in shares of Bristol-Myers Squibb by three.5% within the second quarter. Meiji Yasuda Life Insurance coverage Co now owns 43,015 shares of the biopharmaceutical firm’s inventory valued at $2,397,00zero after buying a further 1,470 shares in the course of the interval. Baltimore Capital Administration Inc. raised its place in shares of Bristol-Myers Squibb by 2.6% within the second quarter. Baltimore Capital Administration Inc. now owns 24,350 shares of the biopharmaceutical firm’s inventory valued at $1,357,00zero after buying a further 610 shares in the course of the interval. Leisure Capital Administration raised its place in shares of Bristol-Myers Squibb by 6.zero% within the second quarter. Leisure Capital Administration now owns three,936 shares of the biopharmaceutical firm’s inventory valued at $219,00zero after buying a further 223 shares in the course of the interval. Hedeker Wealth LLC elevated its place in Bristol-Myers Squibb by 2.5% in the course of the second quarter. Hedeker Wealth LLC now owns 18,996 shares of the biopharmaceutical firm’s inventory value $1,058,00zero after buying a further 468 shares in the course of the interval. Lastly, Intercontinental Wealth Advisors LLC purchased a brand new place in Bristol-Myers Squibb in the course of the second quarter value $1,043,00zero. Institutional traders and hedge funds personal 69.82% of the corporate’s inventory.
Various brokerages not too long ago issued experiences on BMY. Citigroup set a $72.00 goal worth on shares of Bristol-Myers Squibb and gave the inventory a “purchase” score in a analysis report on Tuesday. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “purchase” score to a “maintain” score in a analysis observe on Thursday, November 2nd. SunTrust Banks upgraded shares of Bristol-Myers Squibb from a “maintain” score to a “purchase” score in a analysis observe on Monday, October 30th. Credit score Suisse Group reiterated a “maintain” score and set a $61.00 worth goal (up beforehand from $58.00) on shares of Bristol-Myers Squibb in a analysis observe on Friday, October 27th. Lastly, Piper Jaffray Firms restated a “maintain” score and issued a $60.00 goal worth on shares of Bristol-Myers Squibb in a analysis observe on Friday, October 27th. One analyst has rated the inventory with a promote score, ten have given a maintain score and eleven have assigned a purchase score to the corporate. The corporate at present has a mean score of “Maintain” and a mean worth goal of $64.93.
Shares of Bristol-Myers Squibb Firm (BMY) traded up $zero.58 throughout mid-day buying and selling on Friday, hitting $62.42. The inventory had a buying and selling quantity of 5,266,284 shares, in comparison with its common quantity of four,405,977. The corporate has a present ratio of 1.59, a fast ratio of 1.46 and a debt-to-equity ratio of zero.47. Bristol-Myers Squibb Firm has a one yr low of $46.01 and a one yr excessive of $66.10. The corporate has a market cap of $101,213.53, a PE ratio of 20.89, a PEG ratio of two.34 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) final issued its quarterly earnings information on Thursday, October 26th. The biopharmaceutical firm reported $zero.75 earnings per share (EPS) for the quarter, lacking the Thomson Reuters’ consensus estimate of $zero.77 by ($zero.02). Bristol-Myers Squibb had a internet margin of 20.56% and a return on fairness of 32.41%. The enterprise had income of $5.25 billion in the course of the quarter, in comparison with analyst estimates of $5.20 billion. Throughout the identical quarter within the prior yr, the agency posted $zero.77 earnings per share. Bristol-Myers Squibb’s income for the quarter was up 6.7% in comparison with the identical quarter final yr. analysts anticipate that Bristol-Myers Squibb Firm will publish 2.99 EPS for the present yr.
The corporate additionally not too long ago declared a quarterly dividend, which can be paid on Thursday, February 1st. Shareholders of document on Friday, January fifth can be given a dividend of $zero.40 per share. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 dividend on an annualized foundation and a yield of two.56%. This is a rise from Bristol-Myers Squibb’s earlier quarterly dividend of $zero.39. Bristol-Myers Squibb’s dividend payout ratio is 61.42%.
In different Bristol-Myers Squibb information, EVP Sandra Leung bought 156,582 shares of the corporate’s inventory in a transaction that occurred on Monday, December 4th. The inventory was bought at a mean worth of $63.37, for a complete transaction of $9,922,601.34. Following the completion of the transaction, the manager vp now owns 584,373 shares of the corporate’s inventory, valued at roughly $37,031,717.01. The transaction was disclosed in a authorized submitting with the SEC, which is offered at this hyperlink. Company insiders personal zero.23% of the corporate’s inventory.
TRADEMARK VIOLATION NOTICE: “Stockman Wealth Administration Inc. Has $1.19 Million Stake in Bristol-Myers Squibb Firm (BMY)” was initially printed by StockNewsTimes and is the only property of of StockNewsTimes. In case you are accessing this text on one other publication, it was stolen and reposted in violation of US and worldwide trademark & copyright legal guidelines. The proper model of this text may be considered at https://stocknewstimes.com/2017/12/09/stockman-wealth-management-inc-sells-2030-shares-of-bristol-myers-squibb-company-bmy.html.
Bristol-Myers Squibb Firm Profile
Bristol-Myers Squibb Firm is engaged within the discovery, improvement, licensing, manufacturing, advertising, distribution and sale of biopharmaceutical merchandise. The Firm’s pharmaceutical merchandise embody chemically synthesized medication, or small molecules, and merchandise produced from organic processes known as biologics.
Obtain Information & Scores for Bristol-Myers Squibb Firm Each day – Enter your e-mail tackle beneath to obtain a concise each day abstract of the most recent information and analysts’ scores for Bristol-Myers Squibb Firm and associated corporations with MarketBeat.com’s FREE daily email newsletter.